Top

Current Bladder Dysfunction Reports

Published in:

08-01-2024 | Overactive Bladder | REVIEW

Overactive Bladder: the Patient Perspective

Authors: Victoria S. Edmonds, Aqsa A. Khan

Published in: Current Bladder Dysfunction Reports | Issue 1/2024

Abstract

Purposeof Review

Given that the diagnosis and management of overactive bladder (OAB) is directed by symptomatology, the patient perspective is critical to understanding the disease and efficacy of available treatments. We present a narrative review of literature published in the last 5 years surrounding the patient perspective of OAB.

Recent Findings

OAB has a negative effect on health-related quality of life (HRQoL). Management of OAB generates significant cost to the patient, including physician visits, incontinence pads, treatment of urinary tract infections, and management of skin infections and irritation. Patients with OAB suffer in terms of work productivity, food insecurity, and financial strain, and these effects are more profound in patients of lower socioeconomic status and education level. Recent literature investigating the effect of β3-adrenergic agonists on patient quality of life demonstrated similar improvements when compared with anticholinergics and potentially greater tolerability in terms of adverse effects. In terms of third-line therapies, sacral neuromodulation (SNM) has been shown to have significant improvement in HRQoL and urinary symptoms while avoiding the need for frequent office visits.

Summary

OAB can have a detrimental effect on HRQoL, sexual function, work productivity, and can generate significant cost to the patient. Recent literature demonstrates that existing treatments show promise in terms of improving HRQoL. Patients prefer oral medications over injectable or more invasive therapies; however, a majority of patients who fail medications are willing to trial third-line therapies. Continued investigation of the patient perspective on OAB will be paramount to continue improvement in patient care.

Coyne KS, Sexton CC, Vats V, Thompson C, Kopp ZS, Milsom I. National community prevalence of overactive bladder in the United States stratified by sex and age. Urology. 2011;77(5):1081–7. https://doi.org/10.1016/j.urology.2010.08.039.CrossRefPubMed

Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology. 2003;61(1):37–49. https://doi.org/10.1016/S0090-4295(02)02243-4.CrossRefPubMed

Gormley EA, Lightner DJ, Burgio KL, Chai TC, Clemens JQ, Culkin DJ, et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. J Urol. 2012;188(6 Suppl):2455–63. https://doi.org/10.1016/j.juro.2012.09.079.CrossRefPubMed

Raju R, Linder BJ. Evaluation and treatment of overactive bladder in women. Mayo Clin Proc. 2020;95(2):370–7. https://doi.org/10.1016/j.mayocp.2019.11.024.CrossRefPubMed

Bartoli S, Aguzzi G, Tarricone R. Impact on quality of life of urinary incontinence and overactive bladder: a systematic literature review. Urology. 2010;75(3):491–500. https://doi.org/10.1016/j.urology.2009.07.1325.CrossRefPubMed

Enemchukwu EA, Subak LL, Markland A. Barriers and facilitators to overactive bladder therapy adherence. Neurourol Urodyn. 2022;41(8):1983–92. https://doi.org/10.1002/nau.24936.CrossRefPubMed

Johnston KM, Walker DR, Lakzadeh P. Characterizing the health-related quality of life burden of overactive bladder using disease-specific patient-reported outcome measures: a systematic literature review. Adv Ther. 2019;36(3):548–62. https://doi.org/10.1007/s12325-019-0880-8.CrossRefPubMedPubMedCentral

Brubaker L, Chapple C, Coyne KS, Kopp Z. Patient-reported outcomes in overactive bladder: Importance for determining clinical effectiveness of treatment. Urology. 2006;68(2 Supplement):3–8. https://doi.org/10.1016/j.urology.2006.05.045.CrossRefPubMed

Kim SK, Kim SH. The impact of overactive bladder on health-related quality of life in Korea: based on the results of a Korean Community Health Survey. Qual Life Res. 2021;30(4):1017–24. https://doi.org/10.1007/s11136-020-02710-3.CrossRefPubMed

10.

Kontogiannis S, Athanasopoulos A, Tsagkarakis M, Kontodimopoulos N. Psychometric evaluation of the Overactive Bladder Questionnaire (OAB-q) for measuring quality of life and clinical implications in Greek patients with overactive bladder. Int Urogynecol J. 2022;33(11):3035–43. https://doi.org/10.1007/s00192-021-04991-9.CrossRefPubMed

11.

Gomes CM, Averbeck MA, Koyama M, Soler R. Impact of OAB symptoms on work, quality of life and treatment-seeking behavior in Brazil. Curr Med Res Opin. 2020;36(8):1403–15. https://doi.org/10.1080/03007995.2020.1760806.CrossRefPubMed

12.

Santander J, Plata M, Zuluaga L, Azuero J, Daza F, Trujillo CG, et al. What is the real burden of the overactive bladder? Results from a national prevalence study. Neurourol Urodyn. 2022;41(4):926–34. https://doi.org/10.1002/nau.24894.CrossRefPubMed

13.

• Lin XD, Lin N, Ke ZB, Xu N, Jiang P, Li H. Effects of overactive bladder syndrome on female sexual function. Medicine (Baltimore). 2021;100(20):e25761. https://doi.org/10.1097/md.0000000000025761. Case-control study examining the effect of OAB on female sexual function.CrossRefPubMed

14.

Snedecor SJ. Review of economic value drivers of the treatment of overactive bladder. Pharmacoeconomics. 2018;36(9):1083–92. https://doi.org/10.1007/s40273-018-0663-0.CrossRefPubMed

15.

Iyer S, Amegashie C, deMartelly V, Letko J, Glass D, Fetzer L, et al. Patient perceptions impact progression to third-line therapy for treatment of overactive bladder. J Urol. 2021;206(5):1240–7. https://doi.org/10.1097/ju.0000000000001950.CrossRefPubMed

16.

•• Tellechea L, Zuo S, Kohn JR, Fazzari MJ, Eisenberg R, Lee J, et al. The effect of social determinants of health on overactive bladder symptom severity. J Urol. 2021;205(5):1415–20. https://doi.org/10.1097/ju.0000000000001545. Cross-sectional study demonstrating higher OAB symptom scores are associated with food insecurity, financial strain, difficulty finding or keeping employment, and difficulty concentrating after adjusting for age, race, and BMI.

17.

Kosilov K, Loparev S, Kuzina I, Kosilova L, Prokofyeva A. Socioeconomic status and health-related quality of life among adults and older with overactive bladder. Int J Qual Health Care. 2019;31(4):289–97. https://doi.org/10.1093/intqhc/mzy163.CrossRefPubMed

18.

Roselli N, McKay E, Nauheim J, Halani PK, Abraham NE. Health disparities and access to advanced therapy for overactive bladder. Neurourol Urodyn. 2022;41(8):1940–7. https://doi.org/10.1002/nau.24949.CrossRefPubMed

19.

Zillioux J, Welk B, Suskind AM, Gormley EA, Goldman HB. SUFU white paper on overactive bladder anticholinergic medications and dementia risk. Neurourol Urodyn. 2022;41(8):1928–33. https://doi.org/10.1002/nau.25037.CrossRefPubMed

20.

Athavale A, Gooch K, Walker D, Suh M, Scaife J, Haber A, et al. A patient-reported, non-interventional, cross-sectional discrete choice experiment to determine treatment attribute preferences in treatment-naïve overactive bladder patients in the US. Patient Prefer Adherence. 2018;12:2139–52. https://doi.org/10.2147/ppa.s178668.CrossRefPubMedPubMedCentral

21.

• Herschorn S, Staskin D, Tu LM, Fialkov J, Walsh T, Gooch K, et al. Patient-reported outcomes in patients with overactive bladder treated with mirabegron and tolterodine in a prospective, double-blind, randomized, two-period crossover, multicenter study (PREFER). Health Qual Life Outcomes. 2018;16(1):69. https://doi.org/10.1186/s12955-018-0892-0. Phase IV double-blind crossover study that compared mirabegron and tolterodine ER in treatment-naïve adults with OAB and demonstrated similar improvements in OAB symptom scores.

22.

Carlson KV, Rovner ES, Nair KV, Deal AS, Kristy RM, Schermer CR. Factors associated with improvements in patient-reported outcomes during mirabegron or antimuscarinic treatment of overactive bladder syndrome: a registry study (PERSPECTIVE). Adv Ther. 2019;36(8):1906–21. https://doi.org/10.1007/s12325-019-00994-7.CrossRefPubMedPubMedCentral

23.

Carlson KV, Rovner ES, Nair KV, Deal AS, Kristy RM, Hairston JC. Persistence with mirabegron or antimuscarinic treatment for overactive bladder syndrome: findings from the PERSPECTIVE registry study. Low Urin Tract Symptoms. 2021;13(4):425–34. https://doi.org/10.1111/luts.12382.CrossRefPubMedPubMedCentral

24.

•• Staskin D, Frankel J, Varano S, Shortino D, Jankowich R, Mudd PN Jr. International phase III, randomized, double-blind, placebo and active controlled study to evaluate the safety and efficacy of vibegron in patients with symptoms of overactive bladder: EMPOWUR. J Urol. 2020;204(2):316–24. https://doi.org/10.1097/ju.0000000000000807. Phase III placebo- and active-controlled trial demonstrating the efficacy and safety of vibegron for treatment of OAB.

25.

Frankel J, Varano S, Staskin D, Shortino D, Jankowich R, Mudd PN Jr. Vibegron improves quality-of-life measures in patients with overactive bladder: patient-reported outcomes from the EMPOWUR study. Int J Clin Pract. 2021;75(5):e13937. https://doi.org/10.1111/ijcp.13937.CrossRefPubMed

26.

Kinjo M, Masuda K, Nakamura Y, Miyakawa J, Tambo M, Fukuhara H. Comparison of mirabegron and vibegron in women with treatment-naive overactive bladder: a randomized controlled study. Urology. 2023;175:67–73. https://doi.org/10.1016/j.urology.2023.02.003.CrossRefPubMed

27.

Paudel R, Lane GI. Delivering patient-centered care through shared decision making in overactive bladder. Neurourol Urodyn. 2022;41(4):884–93. https://doi.org/10.1002/nau.24915.CrossRefPubMedPubMedCentral

28.

Speed J, Welk B, Comiter C, Elliott C. Determining patient preferences in the treatment of medication-refractory overactive bladder. Neurourol Urodyn. 2023;42(2):419–26. https://doi.org/10.1002/nau.25109.CrossRefPubMed

29.

••Huang J, Fan Y, Zhao K, Yang C, Zhao Z, Chen Y, et al. Comparative efficacy of neuromodulation technologies for overactive bladder in adults: a network meta-analysis of randomized controlled trials. Neuromodulation. 2022. https://doi.org/10.1016/j.neurom.2022.06.004. Meta-analysis of clinical trials investigating the efficacy and perceived improvement of third-line therapies demonstrated SNM was the most effective for HRQoL improvement, urinary episodes, and urinary frequency.

30.

Sonmez R, Yildiz N, Alkan H. Efficacy of percutaneous and transcutaneous tibial nerve stimulation in women with idiopathic overactive bladder: a prospective randomised controlled trial. Ann Phys Rehabil Med. 2022;65(1):101486. https://doi.org/10.1016/j.rehab.2021.101486.CrossRefPubMed

31.

Kapur A, Harandi AA, Cohen T, Ruan H, Dabrowski C, Anderson R, et al. An analysis of factors that influence patient preference of third-line therapy for overactive bladder. Neurourol Urodyn. 2022;41(8):1906–13. https://doi.org/10.1002/nau.25046.CrossRefPubMed

Title: Overactive Bladder: the Patient Perspective
Authors: Victoria S. Edmonds
Aqsa A. Khan
Publication date: 08-01-2024
Publisher: Springer US
Keyword: Overactive Bladder
Published in: Current Bladder Dysfunction Reports / Issue 1/2024
Print ISSN: 1931-7212
Electronic ISSN: 1931-7220
DOI: https://doi.org/10.1007/s11884-023-00727-1

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Overactive Bladder: the Patient Perspective

Abstract

Purposeof Review

Recent Findings

Summary

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purposeof Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 1/2024

Machine Learning and Artificial Intelligence to Improve Interpretation of Urodynamics

Urinary Biomarkers of Detrusor Underactivity

Use and Outcomes of Botulinum Toxin A for Both Neurogenic and Non-neurogenic Voiding Dysfunction in the Pediatric Patient

Interstitial Cystitis/Bladder Pain Syndrome: Role of Bladder Inflammation in Bladder Function

Using Pictures Instead of Words: Visual-Validated Questionnaires for LUTS and Neurogenic Bladder

In the Era of Holmium Laser Enucleation of the Prostate Is Preoperative Urodynamics Required for Men in Urinary Retention?